Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients

Summary

Atrial fibrillation (AF) is a common complication of coronary artery bypass grafting (CABG). We sought to determine the diagnostic validity of plasma biomarkers of i) inflammation (marked by interleukin-6 [IL-6] and high-sensitivity C-reactive protein [hs-CRP]), ii) extracellular matrix remodelling (matrix metalloproteinase [MMP-9], tissue inhibitor of matrix metalloproteinase [TIMP-1]) and iii) the prothrombotic state (tissue factor and von Willebrand factor [vWF]) in the risk prediction of post-operative AF. Samples were obtained preoperatively from peripheral/femoral vein and from intracardiac chambers (right atrium [RA], the right atrial appendage [RAA], the left atrium [LA] and the left atrial appendage [LAA]) amongst 100 consecutive patients free of AF and inflammatory disease undergoing elective CABG. Biomarker concentrations were related to incident AF (30 days). At 30 days post CABG, 30 patients were proven to have had AF. Concentrations of tissue factor (TF) and vWF were unrelated to postoperative AF. Peripheral (p=0.018), and intracardiac levels (RAA (p=0.029) and LA (p=0.026)) of hs-CRP were associated with the presence of AF after CABG. Intracardiac levels of IL-6 in samples from the RAA (p=0.031), LA (p=0.042) and LAA (p=0.006), and MMP-9 in the LAA sample were also associated with AF (p=0.007). Our data suggest that an intra-cardiac inflammatory environment that is manifest peri-operatively may predispose to the development of post-operative AF. This intracardiac inflammatory state was reflected by increased peripheral hs-CRP levels. These differences may indicate local substrate abnormalities contributing to the development of AF post-operatively.

Keywords

Atrial fibrillation - inflammation - prothrombotic state - remodeling - cardiac surgery

• References

• 1 Lauer MS, Eagle KA, Buckley MJ. et al Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis 1989; 05: 367-368.
• 2 White HD, Antman EM, Glynn MA. et al Efficacy and safety of timolol for the prevention of supraventricular arrhythmias after coronary artery bypass surgery. Circulation 1984; 70: 479-484.
• 3 Andrews TC, Reimold SC, Berlin JA. et al Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991; 84 III 236-244.
• 4 Mathew JP, Fontes ML, Tudor IC. et al A multicenter risk index for atrial fibrillation after cardiac surgery. J Am Med Assoc 2004; 291: 1720-1729.
• 5 Aranki SF, Shaw DP, Adams DH. et al Predictors for atrial fibrillation after coronary artery surgery. Circulation 1996; 94: 390-397.
• 6 Stamou SC, Dangas G, Hill PC. et al Atrial fibrillation after beating heart surgery. Am J Cardiol 2000; 86: 64-67.
• 7 Villareal RP, Hariharan R, Liu BC. et al Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43: 742-748.
• 8 Ahmadi H, Karimi A, Davoodi S. et al 24-hour in-hospital mortality predictions in coronary artery bypass grafting patients. Arch Med Res 2007; 38: 417-423.
• 9 Likosky DS, Leavitt BJ, Marrin CAS. et al Intra- and postoperative predictors of stroke after coronary artery bypass grafting. Ann Thorac Surg 2003; 76: 428-435.
• 10 Borzak S, Tisdale JE, Amin NB. et al Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong hospital stay?. Chest 1998; 113: 1489-1491.
• 11 Chung MK, Martin DO, Sprecher D. et al C-reactive protein elevation in patients with atrial arrhythmias. Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
• 12 Psychari SN, Apostolou TS, Sinos L. et al Relation of elevated C-reactive protein and interleukin-6 levels to atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-767.
• 13 Aviles RJ, Martin DO, Apperson-Hansen C. et al Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010.
• 14 Chen CL, Huang SK, Lin JL. et al Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol 2008; 45: 742-753.
• 15 Nakano Y, Niida S, Dote K. et al Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004; 43: 818-825.
• 16 Conway DS, Buggins P, Hughes E. et al Prognostic significance of raised plasma levels of IL-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462-466.
• 17 Thambidorai SK, Parakh K, Martin DO. et al Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94: 805-807.
• 18 Kirchhof P, Bax J, Blomstrom-Lundquist C. et al Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009; 30: 2969-2977c.
• 19 Edmunds Jr LH. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998; 66: S12-S16.
• 20 Corbi P, Rahmati M, Delwai A. et al Circulating soluble gp130, soluble IL-6R, and IL-6 in patients undergoing cardiac surgery, with or without extracorporeal circulation. Eur J Cardiothorac Surg 2000; 18: 98-103.
• 21 Lo B, Fijnheer R, Nierich AP. et al C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg 2005; 79: 1530-1535.
• 22 Ucar I H, Tok M, Atalar E, Dogan OF. et al Predictive significance of plasma levels of interleukin-6 and high-sensitivity C-reactive protein in atrial fibrillation after coronary artery bypass surgery. Heart Surg Forum 2007; 10: E131-135.
• 23 Fontes ML, Mathew JP, Rinder HM. et al. and the Multicenter Study of Perioperative Ischemia (McSPI) Reasearch Group. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth Analg 2005; 101: 17-23.
• 24 Ahlsson AJ, Bodin L, Lundblad OH. et al Postoperative atrial fibrillation is not correlated to C-reactive protein. Ann Thorac Surg 2007; 83: 1332-1337.
• 25 Danesh J, Whincup P, Walker M. et al Low grade inflammation and coronary heart. Br Med J 2000; 321: 199-204.
• 26 Ak K, Akgun S, Tecimer T. et al Determination of histopathologic risk factors for postoperative atrial fibrillation in cardiac surgery. Ann Thorac Surg 2005; 79: 1970-1975.
• 27 Mariscalco G, Engstrom KG, Ferrareze S. et al Relationship between atrial histopathology and atrial fibrillation after coronary bypass surgery. J Thorac Cardiovasc Surg 2006; 131: 1364-1372.
• 28 Nakai T, Chandy J, Nakai K. et al Histologic assessment of right atrial appendage myocardium in patients with atrial fibrillation after coronary artery bypass graft surgery. Cardiology 2007; 108: 90-96.
• 29 Brauer PR. MMPs – role in cardiovascular development and disease. Front Biosci 2006; 11: 447-478.
• 30 Mukherjee R, Herron AR, Lowry AS. et al Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006; 97: 532-537.
• 31 Gramley F, Lorenzen J, Plisiene J. et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 1076-82.
• 32 Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
• 33 Mondillo S, Sabatini L, Agricola E. et al Correlation between left atrial size, pro-thrombotic state and markers of endothelial dysfunction in patients with lone chronic non-rheumatic atrial fibrillation. Int J Cardiol 2000; 75: 227-232.
• 34 Freestone B, Chong AY, Nuttall S. et al Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132: 1253-1258.
• 35 Roldán V, Marin F, Blann AD. et al Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24: 1373-1380.
• 36 Chung NA, Belgore F, Li-Saw-Hee FL. et al Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?. Stroke 2002; 33: 2187-2191.
• 37 Goldsmith I, Kumar P, Carter P. et al Atrial endocardial changes in mitral valve disease: A scanning electron microscopy study. Am Heart J 2000; 140: 777-784.
• 38 Boyaci A, Topaloglu S, Yilmaz S. et al Regional left atrial coagulation and fibrinolytic activities in patients with mitral stenosis. Jpn Heart J 2004; 45: 779-788.
• 39 Li-Saw-Hee FL, Blann AD, Goldsmith I. et al Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol 1999; 83: 1206-1209.
• 40 Prasongsukarn K, Abel JG, Jamieson WR. et al The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial. J Thorac Cardiovasc Surg 2005; 130: 93-98.
• 41 Carnes CA, Chung MK, Nakayama T. et al Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89: E32-38.
• 42 Calò L, Bianconi L, Colivicchi F. et al N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005; 45: 1723-1728.
• 43 Patti G, Chello M, Candura D. et al Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-1461.